drugset / Trial / NCT01859455

Safety, Pharmacokinetics and Pharmacodynamics of LGT209 in Healthy Volunteers With Elevated Cholesterol and in Hypercholesterolemic Patients Treated With Statins

NCT01859455

Phase 1 Completed 25 enrolled Novartis Pharmaceuticals
RandomizedParallel-groupDouble-blindTreatment

Summary

This study is designed to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of LGT209 in hypercholesterolemic patients taking common statin medications and in healthy volunteers.

Timeline

Start
2011-07
Primary completion
2012-07
Completion
2012-07

Drugs

EvaluationDrugModalityDoseRoute
Subject LGT209 Unknown 50 mg Subcutaneous
Subject LGT209 Unknown 300 mg Subcutaneous
Background Atorvastatin Small molecule
Background Simvastatin Small molecule